The future of ERT in catalysis looks promising with ongoing research focused on overcoming current limitations. Innovations in CRISPR-Cas9 and other gene-editing technologies hold potential for permanent correction of enzyme deficiencies. Furthermore, advances in biomaterials and drug delivery systems are likely to enhance the precision and efficacy of enzyme therapies, making ERT a more viable and effective treatment option for a broader range of genetic disorders.
